June 25, 2024
Primary Sclerosing Cholangitis Market

Primary Sclerosing Cholangitis Market Driven By Growing Prevalence And Awareness Of Disease

Primary sclerosing cholangitis (PSC) is a rare chronic liver disease characterized by inflammation and scarring of the bile ducts within the liver. Symptoms of PSC include fatigue, itching, jaundice and abnormal liver function tests. The disease can progress to cirrhosis and liver failure if left untreated. Since PSC often occurs with inflammatory bowel disease such as ulcerative colitis and Crohn’s disease, those diagnosed with IBD should be routinely screened for liver disease. Treatment centers around managing symptoms, monitoring for complications and considering liver transplant for patients with advanced disease.

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 350 million in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Growing research into risk factors, diagnosis and treatment of PSC is driving innovation and drug development. Increasing public awareness through patient advocacy groups like the PSC Partners Seeking a Cure organization is improving early detection rates. Promising drug candidates in clinical trials include firsocostat and bezafibrate which reduce bile acid levels and inflammation respectively. Combination therapies targeting multiple disease mechanisms show potential to ease symptoms and slow progression in those with mild to moderate PSC. Advancements in liver transplantation techniques and immunosuppressants also expand treatment options for end-stage liver disease. Overall, greater understanding of disease pathogenesis at the molecular level is enabling development of more targeted and effective PSC therapies.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the primary sclerosing cholangitis market is low as it requires large investments in research and development to develop novel treatment options.

Bargaining power of buyers: The bargaining power of buyers is moderate as the options for treatment of primary sclerosing cholangitis are limited currently.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are several pharmaceutical companies engaged in supplying drugs for primary sclerosing cholangitis treatment.

Threat of new substitutes: There is limited threat of new substitutes currently as no alternative approach for primary sclerosing cholangitis treatment has proven effective.

Competitive rivalry: Competition in the market is high among existing players who are engaged in developing new and improved treatment approaches.

Key Takeaways

The global primary sclerosing cholangitis market size is expected to witness steady growth over the forecast period. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 350 million in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030.

Regional analysis: North America is expected to hold a major share of the primary sclerosing cholangitis market over the forecast period. The growing number of research studies being conducted for developing novel treatment approaches and higher healthcare expenditure are contributing to market growth. Asia Pacific is anticipated to witness fastest growth over the forecast period supported by expanding healthcare infrastructure and increasing healthcare investment in countries like China and India.

Key players: Key players operating in the primary sclerosing cholangitis market include Intercept Pharmaceuticals, Dr. Falk Pharma, Gilead Sciences, HighTide Therapeutics, GlaxoSmithKline,NGM Biopharmaceuticals, and Takeda Pharmaceuticals. Intercept Pharmaceuticals’ obeticholic acid (Ocaliva) is currently the only approved drug for treatment of primary sclerosing cholangitis.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it